USP9Y Activators
USP9Y (Ubiquitin-specific peptidase 9, Y-linked) is part of the ubiquitin-specific proteases family, playing a role in the process of deubiquitination, which is critical for maintaining protein stability and function. Given the lack of direct chemical activators, attention is directed to compounds that influence the ubiquitin-proteasome system and related cellular processes, potentially modulating USP9Y activity indirectly.
Proteasome inhibitors like MG132, Bortezomib, and Epoxomicin may affect the cellular environment of protein degradation, potentially impacting USP9Y's role in this process. Broad-spectrum DUB inhibitors (e.g., PR-619) and specific inhibitors like LDN-57444 (UCH-L1 inhibitor) offer insights into the regulation of deubiquitination processes relevant to USP9Y. Compounds affecting the ubiquitination process itself, such as PYR-41 (an E1 inhibitor), and agents modulating protein degradation pathways, including Thalidomide and its analogs (Lenalidomide, Pomalidomide), provide alternative routes to influence USP9Y activity. Tyrosine kinase inhibitors like Nilotinib and Dasatinib may impact USP9Y indirectly through alterations in cell signaling pathways. Additionally, Rapamycin, as an mTOR inhibitor, represents another avenue for indirect modulation, given mTOR's central role in cellular metabolism and growth.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, potentially affecting USP9Y's role in protein degradation by altering proteasomal activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor, could indirectly influence USP9Y by modifying the cellular protein degradation environment. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor, potentially impacting USP9Y activity through effects on protein turnover. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
A broad-spectrum DUB inhibitor, it might indirectly affect USP9Y's function within the ubiquitin-proteasome system. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An inhibitor of ubiquitin activating enzyme E1, potentially affecting the ubiquitination process relevant to USP9Y's function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates protein degradation pathways, potentially influencing USP9Y activity through its effects on the proteasome system. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Similar to Thalidomide, affects protein degradation pathways, which could indirectly impact USP9Y. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Another IMiD agent affecting proteasome activity, potentially influencing USP9Y indirectly. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
A tyrosine kinase inhibitor, could indirectly affect USP9Y by altering signaling pathways involved in cell survival and growth. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Another tyrosine kinase inhibitor, potentially affecting USP9Y activity through cellular signaling pathways. | ||||||